Guo YX, Yan X, Liu XC, Liu YX, Liu C. Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease. World J Nephrol 2025; 14(1): 100825 [DOI: 10.5527/wjn.v14.i1.100825]
Corresponding Author of This Article
Chun Liu, DPhil, Chief Doctor, Professor, Surgeon, No. 1 Clinical Medical School, Shanxi Medical University, No. 56 Xinjian South Road, Taiyuan 030001, Shanxi Province, China. sxtyliuchun@126.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Mar 25, 2025; 14(1): 100825 Published online Mar 25, 2025. doi: 10.5527/wjn.v14.i1.100825
Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease
Ya-Xiong Guo, Xiong Yan, Xu-Chang Liu, Yu-Xiang Liu, Chun Liu
Ya-Xiong Guo, Surgical Unit 1, Shanxi Combined Traditional Chinese and Western Medicine Hospital, Taiyuan 030072, Shanxi Province, China
Ya-Xiong Guo, Xiong Yan, Xu-Chang Liu, Chun Liu, No. 1 Clinical Medical School, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Yu-Xiang Liu, Department of Nephrology, Shanxi Provincial People’s Hospital, Taiyuan 030012, Shanxi Province, China
Co-corresponding authors: Yu-Xiang Liu and Chun Liu.
Author contributions: Liu C designed the overall concept and outline of the manuscript; Guo YX and Liu YX contributed to the discussion and design of the manuscript; Liu XC and Yan X contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun Liu, DPhil, Chief Doctor, Professor, Surgeon, No. 1 Clinical Medical School, Shanxi Medical University, No. 56 Xinjian South Road, Taiyuan 030001, Shanxi Province, China. sxtyliuchun@126.com
Received: August 27, 2024 Revised: November 29, 2024 Accepted: December 27, 2024 Published online: March 25, 2025 Processing time: 145 Days and 23.7 Hours
Abstract
In this editorial, we discuss the article by Singh et al published in World Journal of Nephrology, stating the need for timely adjustments in inflammatory bowel disease (IBD) patients' long-term management plans. IBD is chronic and lifelong, with recurrence and remission cycles, including ulcerative colitis and Crohn's disease. It's exact etiology is unknown but likely multifactorial. Related to gut flora and immune issues. Besides intestinal symptoms, IBD can also affect various extraintestinal manifestations such as those involving the skin, joints, eyes and urinary system. The anatomical proximity of urinary system waste disposal to that of the alimentary canal makes early detection and the differentiation of such symptoms very difficult. Various studies show that IBD and it's first-line drugs have nephrotoxicity, impacting the patients' life quality. Existing guidelines give very few references for kidney lesion monitoring. Singh et al's plan aims to improve treatment management for IBD patients with glomerular filtration rate decline, specifically those at risk. Most of IBD patients are young and they need lifelong therapy. So early therapy cessation, taking into account drug side effects, can be helpful. Artificial intelligence-driven diagnosis and treatment has a big potential for management improvements in IBD and other chronic diseases.
Core Tip: Inflammatory bowel disease (IBD) requires long-term continuous drug therapy. However, many current first-line drugs exhibit nephrotoxicity or potential nephrotoxic induction with prolonged use. Artificial intelligence can assist in analyzing and adjusting treatment plans, offering theoretical prospects for long-term IBD management. Establishing a comprehensive and accurate database of clinical predictive indicators is crucial.
